Table 2 Summary of allergic adverse events during LTFU
From: Feasibility of sustained response through long-term dosing in food allergy immunotherapy
Reaction numbers and % of total reactions | Total | Month 0–12 | Month 13–24 | Month 25–36 | Month 37–48 | Month 49–72 |
|---|---|---|---|---|---|---|
Number of participants followed during time period | 46 | 46 | 46 | 41 | 23 | |
Total ITT reactions | 1207 | 822 | 261 | 114 | 10 | 0 |
Gastrointestinal | 109 (9.03%) | 82 (9.98%) | 17 (6.51%) | 10 (8.77%) | 0 | 0 |
Mild | 107 | 80 | 17 | 10 | 0 | 0 |
Moderate | 2 | 2 | 0 | 0 | 0 | 0 |
Severe | 0 | 0 | 0 | 0 | 0 | 0 |
Respiratory/thoracic/mediastinal | 75 (6.21%) | 70 (8.52%) | 3 (1.15%) | 2 (1.75%) | 0 | 0 |
Mild | 70 | 70 | 0 | 0 | 0 | 0 |
Moderate | 5 | 0 | 3 | 2 | 0 | 0 |
Severe | 0 | 0 | 0 | 0 | 0 | 0 |
Skin/subcutaneous | 403 (33.39%) | 251 (30.54%) | 99 (37.93%) | 53 (46.49%) | 0 | 0 |
Mild | 286 | 162 | 75 | 49 | 0 | 0 |
Moderate | 115 | 88 | 23 | 4 | 0 | 0 |
Severe | 2 | 1 | 1 | 0 | 0 | 0 |
Eye | 25 (2.07%) | 16 (1.95%) | 7 (2.68%) | 2 (1.75%) | 0 | 0 |
Mild | 25 | 16 | 7 | 2 | 0 | 0 |
Moderate | 0 | 0 | 0 | 0 | 0 | 0 |
Severe | 0 | 0 | 0 | 0 | 0 | 0 |
Cardiovascular | 0 | 0 | 0 | 0 | 0 | 0 |
Nasal congestion | 286 (23.7%) | 166 (20.19%) | 85 (32.57%) | 35 (30.7%) | 0 | 0 |
Mild | 276 | 157 | 84 | 35 | 0 | 0 |
Moderate | 7 | 6 | 1 | 0 | 0 | 0 |
Severe | 3 | 3 | 0 | 0 | 0 | 0 |
Other (i.e. anxiety) | 309 (25.6%) | 237 (28.83%) | 50 (19.16%) | 12 (10.53%) | 10 (100%) | 0 |
Mild | 309 | 237 | 50 | 12 | 10 | 0 |
Moderate | 0 | 0 | 0 | 0 | 0 | 0 |
Severe | 0 | 0 | 0 | 0 | 0 | 0 |